Passage Bio is a biotechnology business based in the US. Passage Bio shares (PASG) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.47 – a decrease of 29.49% over the previous week. Passage Bio employs 58 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.47 |
|---|---|
| 52-week range | $0.54 - $1.79 |
| 50-day moving average | $0.65 |
| 200-day moving average | $1.01 |
| Wall St. target price | $7.67 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.37 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.519 from 2024-11-15
| 1 week (2024-11-12) | -22.31% |
|---|---|
| 1 month (2024-10-18) | -10.44% |
| 3 months (2024-08-19) | -28.90% |
| 6 months (2024-05-17) | -60.68% |
| 1 year (2023-11-17) | -13.50% |
|---|---|
| 2 years (2022-11-18) | -61.56% |
| 3 years (2021-11-19) | 8.38 |
| 5 years (2019-11-16) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -34.48% |
| Return on equity TTM | -63.55% |
| Profit margin | 0% |
| Book value | $1.47 |
| Market Capitalization | $36.5 million |
TTM: trailing 12 months
We're not expecting Passage Bio to pay a dividend over the next 12 months.
Over the last 12 months, Passage Bio's shares have ranged in value from as little as $0.54 up to $1.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Passage Bio's is 1.196. This would suggest that Passage Bio's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Passage Bio, Inc. , a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.